Avita Medical RCEL 深 沪
交易中 07-10 11:33:41 美东时间
4.1438
-0.266
-6.04%
华盛通- 最 高4.40
- 今 开4.40
- 成交量 2.54万股
- 最 低 4.1438
- 昨 收 4.41
- 总市值 1.28亿
- 52周最高 7.12
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 3.22
- 委 比 3.98%
- 总股本 3077.67万
- 历史最高 49.11
- 量 比 0.27
- 振 幅 5.81%
- 历史最低 3.22
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Avita Medical says UK case series supports RECELL GO use in burn surgery patients
Avita Medical says UK case series supports RECELL GO use in burn surgery patients Avita Medical highlighted first U.K. clinical experience with its RECELL GO device, with results already presented at the 2026 British Burn Association meeting. A case series of 17 burn and reconstructive surgery patie
06-18 20:40
Avita Medical shareholders approve non-executive director equity awards at annual meeting
Avita Medical shareholders approve non-executive director equity awards at annual meeting Avita Medical held its annual shareholder meeting on June 3, 2026. Shareholders ratified Grant Thornton LLP as independent registered public accounting firm for the year ending Dec. 31, 2026. Shareholders autho
06-04 18:03
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
电话会总结 ｜ Avita(RCEL)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据AVITA Medical业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** 2026年第一季度营收1,930万美元，同比增长4%，环比增长约10%（相比2025年第四季度），为过去一年中最高季度营收。 **盈利能力：** 毛利率81.7%，净亏损1,060万美元（每股亏损0.35美元），较上年同期净亏损1,390万美元（每股亏损0.53美元）有所改善。 **现金状况：** 季度净现金消耗990万美元，期末现金及有价证券余额1,430万美元。 **成本控制：** 运营费用2,450万美元，同比下降11%。 ## 2.
05-16 12:12
Lake Street Upgrades AVITA Medical to Buy, Raises Price Target to $6
Lake Street analyst Frank Takkinen upgrades AVITA Medical (NASDAQ:RCEL) from Hold to Buy and raises the price target from $3.5 to $6.
05-16 01:44
AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript
AVITA Medical (NASDAQ:RCEL) released first-quarter financial results and hosted...
05-15 05:26
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
AVITA Medical Appoints Cary Vance President, CEO; Jan Stern As Board Chair, Effective Immediately
AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective
04-30 20:52
Avita Medical names Cary Vance CEO after interim tenure
Avita Medical names Cary Vance CEO after interim tenure Avita Medical appointed Cary Vance as president, chief executive officer, effective immediately. Vance served as interim CEO since October 2025. Board elected Jan Stern Reed as chair, effective immediately. Reed has served on board since 2021.
04-30 20:50
AVITA Medical Enters Into 10-Yr Agreement With BARDA Valued At Up To $25.5M To Strengthen National Preparedness For Burn Mass Casualty Incidents
Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BARDA access to 3,000 units any time over the 10-year contract VALENCIA, Calif., April 08, 2026 (GLOBE NEWSWIRE)
04-09 04:17
